Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor - 28/08/20
, Wenjie Xu a, Huaijie Hua a, Ying Xiao a, Xiaoyan Chen b, Zhiwei Gao b, Song Li a, Xiaolong Jing a, Frank Du c, Guofeng Sun cBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
| páginas | 10 |
| Iconografías | 10 |
| Vídeos | 0 |
| Otros | 0 |
Graphical abstract |
Highlights |
• | S086 is a novel ARNi, potentially superior to LCZ696. |
• | S086 showed a significant anti-HF effect in two MI models. |
• | Those effects of S086 were comparable to LCZ696. |
• | S086 displayed a druggable PK profile. |
• | This study firstly showed the anti-HF pharmacological effect of ARNi on MI dog model. |
Abstract |
Background and Purpose |
Angiotensin receptor-NEP inhibitor (ARNi), which includes an angiotensin receptor blocker (ARB) and a neprilysin inhibitor (NEPi), has been proven safe and effective for treating heart failure with reduced ejection fraction (HF-REF). S086 is a novel single-molecule ARNi that includes the molecular moieties of EXP3174 (the active metabolite of the ARB losartan) and sacubitril (a NEP inhibitor prodrug) in a 1:1 M ratio. We performed preclinical animal model studies to evaluate the efficacy of S086 in treating HF.
Experimental Approach |
Rat and dog models of myocardial ischemia-induced chronic heart failure were used in this research.
Principal Results |
The oral administration of S086 dose-dependently lowered the heart weight index, attenuated cardiac fibrosis, and improved left ventricular ejection fraction, shortening fraction, and cardiac output, without effects on hemodynamics in animal models of myocardial ischemia-induced chronic heart failure. A comparable protective effect to LCZ696 was observed for S086 at an equal molar dose in dog models. In addition, S086 was superior to LCZ696 since it significantly reversed the decrease in left ventricular posterior wall end-systolic thickness.
Conclusion |
This animal study suggests that S086 is effective in treating myocardial ischemia-induced chronic heart failure.
El texto completo de este artículo está disponible en PDF.Abbreviations : ARNi, ARB, NEPi, HF, HF-REF, RAAS, ANP, BNP, ACE, MI, LAD, LVPW, LVPWTd, LVPWTs, LVEF, FS, CO, SP, DP, LVSP, LVEDP, PK
Keywords : Angiotensin receptor-NEP inhibitor, Heart failure, Neprilysin inhibitor, Angiotensin receptor blocker
Esquema
Vol 129
Artículo 110410- septembre 2020 Regresar al número
Artículo precedente
- Epigallocatechin-3-gallate protects immunity and liver drug-metabolism function in mice loaded with restraint stress
- Huaqiao Tang, Suqi Hao, Xingying Chen, Yinglun Li, Zhongqiong Yin, Yuanfeng Zou, Xu Song, Lixia Li, Gang Ye, Ling Zhao, Hongrui Guo, Ran He, Cheng Lv, Juchun Lin, Fei Shi
- SPI1-induced upregulation of lncRNA SNHG6 promotes non-small cell lung cancer via miR-485-3p/VPS45 axis
- Nan Gao, Baoguo Ye
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?